Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-018336

PRESIDENT AND CEO sold 12,000 shares at an average $21.66 ($259,902)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-06-25 Sale : show line 1 in the form 10b5-1 −11,422 $21.63 $247,014 1,076,103 I
2024-06-25 Sale : show line 2 in the form 10b5-1 −578 $22.30 $12,887 1,075,525 I
Open-market sales · 12,000 sh · avg $21.66 · $259,902
Loading xslF345X05/form4-06272024_080620.xml…